Multi-omics analysis reveals drivers of loss of β-cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study.
Jose Juan Almagro ArmenterosCaroline BrorssonChristian Holm JohansenKarina BanasikGianluca MazzoniRobert MoulderM Karoliina HirvonenTomi SuomiOmid RasoolSylvaine F A BruggraberM Loredana MarcovecchioA Emile J HendriksNaba Al-SariIsmo MattilaCristina Legido-QuigleyTommi SuvitaivalPiotr J ChmuraMikael KnipAnke M SchulteJeong Heon LeeGuido SebastianiGiuseppina Emanuela GriecoLaura L EloSimranjeet KaurFlemming PociotFrancesco DottaTim TreeRiitta LahesmaaLut OverberghChantal MathieuMark PeakmanSoren Brunaknull nullPublished in: Diabetes/metabolism research and reviews (2024)
Features that differ between individuals with slow and rapid decline in β-cell mass could be valuable in staging and prediction of the rate of disease progression and thus enable smarter (shorter and smaller) trial designs for disease modifying therapies as well as offering biomarkers of therapeutic effect.